Products
Efmoroctocog alfa was approved in many countries in 2016 as a powder and solvent for the preparation of a solution for injection (Elocta).
Structure and properties
Efmoroctocog alfa is a recombinant fusion protein consisting of human coagulation factor VIII without the B domain covalently bound to the Fc domain of human immunoglobulin G1. The Fc domain binds to the neonatal Fc receptor. This results in a long half-life.
Effects
Efmoroctocog alfa (ATC B02BD02) replaces factor VIII, which is insufficient in hemophilia A. It reduces the risk of bleeding by normalizing blood clotting.
Indications
For the treatment and prevention of bleeding in pretreated patients with hemophilia A (congenital factor VIII deficiency).
Dosage
According to the SmPC. The drug is injected intravenously over several minutes.
Contraindications
- Hypersensitivity
he full precautions can be found in the drug label.
Interactions
Drug-drug interactions are not known.
Adverse effects
There is a risk for allergic reactions.
